Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients
Related Experiment Videos
D M Adams1, W H Schultz, R E Ware
1Duke-UNC Comprehensive Sickle Cell Center, Duke University Medical Center, Durham, NC 27710, USA.
Insights
Erythrocytapheresis is a safe and effective treatment for young pediatric patients requiring chronic erythrocyte transfusions. This method helps reduce iron overload and may eliminate the need for costly chelation therapy.
Area of Science:
- Pediatric Hematology
- Transfusion Medicine
Background:
- Chronic erythrocyte transfusion therapy is essential for managing various pediatric conditions.
- Iron overload is a significant complication of long-term transfusion therapy, necessitating management strategies.
- Erythrocytapheresis offers a potential solution for managing transfusion-dependent pediatric patients.
Purpose of the Study:
- To evaluate the advantages, complications, costs, and efficacy of erythrocytapheresis in young pediatric patients undergoing chronic erythrocyte transfusion.
- To compare erythrocytapheresis with simple transfusion therapy in terms of blood unit exposure, alloimmunization, and cost-effectiveness.
- To assess the impact of erythrocytapheresis on serum ferritin levels and iron burden.
Main Methods:
- Retrospective analysis of data from 10 pediatric patients who underwent erythrocytapheresis for an average of 16 months.
- Comparison of annual blood unit exposure, alloimmunization rates, and costs between erythrocytapheresis and simple transfusion.
- Monitoring of serum ferritin levels before and after the implementation of erythrocytapheresis.
Main Results:
- Erythrocytapheresis was well-tolerated in children as young as 5 years or weighing 20 kg.
- While requiring higher annual blood unit exposure, erythrocytapheresis did not increase alloimmunization rates.
- Significant reduction in ferritin levels was observed in patients on concurrent deferoxamine therapy, with stabilization or decrease in others; iron overload was prevented in children initiated on therapy soon after stroke.
Conclusions:
- Erythrocytapheresis is a safe and effective therapeutic option for young pediatric patients requiring chronic erythrocyte transfusions.
- The procedure can effectively reduce the total iron burden in these patients.
- Erythrocytapheresis may obviate the need for expensive iron chelation therapy, offering a cost-effective alternative in the long term.
Purpose:
This research was undertaken to determine the advantages, complications, costs, and efficacy of erythrocytapheresis in young pediatric patients who receive chronic erythrocyte transfusion therapy.
Patients And Methods:
We retrospectively analyzed data for 10 children who received erythrocytapheresis for an average of 16 months. Erythrocytapheresis was compared to simple transfusion therapy with respect to annual blood unit exposure, occurrence of alloimmunization, and costs. Serum ferritin levels were compared before and after the period of erythrocytapheresis.
Results:
Erythrocytapheresis was well tolerated, even in children as young as 5 years or as small as 20 kg. It required a greater annual unit exposure than simple transfusions, but did not increase alloimmunization. Ferritin levels decreased significantly in children receiving concurrent deferoxamine, and decreased or stabilized in those not on chelation therapy. Children started on erythrocytapheresis soon after stroke have not developed iron overload. Although the costs of erythrocytapheresis exceed that of simple transfusion, the substantial costs of deferoxamine therapy should be considered; one child on erythrocytapheresis has been able to discontinue chelation therapy following normalization of his ferritin level.
Conclusion:
Erythrocytapheresis is a safe and effective method for young patients receiving chronic erythrocyte transfusions. Erythrocytapheresis can reduce total iron burden and may obviate the need for expensive chelation therapy.